Grifols

Grifols EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Grifols (GRF.MC) as of Sep 19, 2026 is 1.22 B EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 1.31 B EUR — a change of -6.84% (lower).

EBITDA

1.22 BEUR

YoY

-6.84%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Grifols is 2026 1.22 B EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Grifols was 2025 1.31 B EUR. It decreases by -6.84% lower compared to the previous year.

The Grifols EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
1.08 B EUR
Jan 1, 2019
1.25 B EUR
Jan 1, 2020
1.12 B EUR
Jan 1, 2021
743.16 M EUR
Jan 1, 2022
938.03 M EUR
Jan 1, 2023
909.79 M EUR
Jan 1, 2024
1.31 B EUR
Jan 1, 2025
1.22 B EUR
The Grifols EBITDA history
YEAREBITDAYoY
1.22 BEUR-6.84%
1.31 BEUR+43.96%
909.79 MEUR-3.01%
938.03 MEUR+26.22%
743.16 MEUR-33.61%
1.12 BEUR-10.51%
1.25 BEUR+16.23%
1.08 BEUR+1.98%
1.06 BEUR+4.04%
1.01 BEUR-3.33%
1.05 BEUR+8.62%
965.94 MEUR
Access this data via the Eulerpool API

Grifols Stock analysis

What does Grifols do? Grifols SA is a globally operating company specialized in the manufacture and marketing of medical products and technologies. The company is headquartered in Barcelona, Spain and has been in existence for over 75 years. Grifols focuses on improving the quality of life through the production and marketing of blood products and services, diagnostics, and hospital pharmaceuticals. It has four main business areas: Bioscience, Hospital, Diagnostic, and Bio Supplies. Grifols emphasizes research and development to meet customer needs. It has introduced various products, including AlfaBIO, Vistogard, ID Core XT, NEO Blood Bank, and MIRASOL Pathogen Reduction Technology. Grifols is committed to innovation and quality, providing products and services that cater to a wide range of customers. Additionally, it is a significant employer in the biotechnology industry and contributes to economic development in different regions. Grifols is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Grifols stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Grifols is 1.22 B EUR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Grifols changed from 1.31 B EUR to 1.22 B EUR, representing a -6.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Grifols since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Grifols historically and in real time.

Access this data via the Eulerpool API

Income Statement — Grifols

All Key Metrics — Grifols